Lobe Sciences Ltd. to Attend D. Boral Capital Global Conference

Lobe Sciences Ltd., a Vancouver-based clinical-stage biopharmaceutical company, announced its participation in the D. Boral Capital Global Conference on May 7, 2026, in New York City. CEO Dr. Frederick D. Sancilio will attend, engaging with investors and partners about Lobe's therapeutic programs.

The company focuses on developing high-potential drug candidates, specifically through subsidiaries. Lobe's model emphasizes the development of formulations, intellectual property, and regulatory engagement. Two drugs, L-130 and S-100, are under development. L-130, developed by Cynaptec Pharmaceuticals, aims to stabilize psilocin, while S-100, from Applied Lipid Therapeutics, targets sickle cell disease with a lipid-based delivery system.

Interested parties can schedule meetings with Dr. Sancilio by contacting the company.